Zydus, Formycon’s Keytruda biosimilar FYB206 accepted for USFDA review EP News Bureau Oct 13, 2026 The BLA was submitted in Q3 2026, with a regulatory decision potentially expected in Q3 2027
OneSource Specialty Pharma and Formycon AG announce strategic manufacturing partnership for… EP News Bureau Jul 14, 2026 OneSource Specialty Pharma, a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, "Formycon"), an…
Zydus Lifesciences signs licensing deal with Formycon EP News Bureau Dec 10, 2025 Formycon to develop and supply Pembrolizumab biosimilar FYB206, while Zydus Lifesciences will commercialise the product in the USA…
